Race Oncology

Race Oncology (RAC) shares was listed on the Australian Stock Exchange on July 13, 2016 and is in the Health Care sector. RACE ONCOLOGY LTD formerly Coronado Resources Limited, is a specialty pharmaceutical company, whose business model is to pursue later stage drug assets, principally in the cancer field. Race Oncology's first important asset is a chemotherapy drug, called Bisantrene, which was the subject of more than 40 phase II clinical studies, before it was lost in a series of pharmaceutical mergers during the 1990s.